{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:06:47Z","timestamp":1791925607525,"version":"4.3.4"},"reference-count":96,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005066","name":"Key Medical of Jiangsu Province","doi-asserted-by":"publisher","award":["ZDXKB2016020"],"award-info":[{"award-number":["ZDXKB2016020"]}],"id":[{"id":"10.13039\/501100005066","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guo Qinglong 2016 Nanjing Emerging Industry Guidance Special Fund","award":["YY2016120701"],"award-info":[{"award-number":["YY2016120701"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Hematology"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/16078454.2022.2074704","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T14:59:00Z","timestamp":1653663540000},"page":"642-652","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia"],"prefix":"10.1080","volume":"27","clinical-trial-number":[{"clinical-trial-number":"nct01363297","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04546399","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02877303","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04681105","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03677596","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02879695","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04601584","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01363128","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02000427","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04224571","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03441061","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03094611","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03913559","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02013167","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02458014","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02981628","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01564784","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04684147","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03739814","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01466179","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03698552","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01371630","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Zheng","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqian","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33018-1"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.8018"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1636"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29383"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085554"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09095.x"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.1382"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.7265"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.229"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8192"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0752-8"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.312"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010306"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-151860"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140582"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23522"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563627"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01317-3"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.11.010"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605085"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.362"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.27.9836"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60027-7"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348656"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403559"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20071"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30144-7"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881961"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8192"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.265"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4544"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24419"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.229"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.7265"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20908"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.559668"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000874"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-547695"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13834"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0580"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377713"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.145631"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2337"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1780583"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32335"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004008"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00261"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.246"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0704"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-052746"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1287"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.08.021"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.116954"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-771121"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.3531"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32558"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1844198"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.02.009"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25410"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2014.09.014"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.10.021"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438002"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.206"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2466"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32116"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31249"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30103-5"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001925"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.04.020"},{"key":"CIT0082","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0265-z"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2380"},{"key":"CIT0084","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30011-1"},{"key":"CIT0085","unstructured":"Clinicaltrials.gov. Chinese Children Cancer Group Relapsed Acute Lymphoblastic Leukemia 2017 Study. Available at: www.clinicaltrials.gov (NCT04224571)."},{"key":"CIT0086","unstructured":"Clinicaltrials.gov. Phase II Study of Blinatumomab in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease. Available at: www.clinicaltrials.gov (NCT02458014)."},{"key":"CIT0087","unstructured":"Clinicaltrials.gov. A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged\u2009\u2265\u20091 to < 31 Years Old With First Relapse. Available at: www.clinicaltrials.gov (NCT04546399)."},{"key":"CIT0088","unstructured":"Clinicaltrials.gov. A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia. Available at: www.clinicaltrials.gov (NCT02879695)."},{"key":"CIT0089","unstructured":"Clinicaltrials.gov. Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia. Available at: www.clinicaltrials.gov (NCT03913559)."},{"key":"CIT0090","unstructured":"Clinicaltrials.gov. Phase II Study of Inotuzumab Ozogamicin in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease. Available at: www.clinicaltrials.gov (NCT03441061)."},{"key":"CIT0091","unstructured":"Clinicaltrials.gov. A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease. Available at: www.clinicaltrials.gov (NCT03739814)."},{"key":"CIT0092","unstructured":"Clinicaltrials.gov. Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab With or Without Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia. Available at: www.clinicaltrials.gov (NCT02877303)."},{"key":"CIT0093","unstructured":"Clinicaltrials.gov. A Phase I\/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Available at: www.clinicaltrials.gov (NCT03698552)."},{"key":"CIT0094","unstructured":"Clinicaltrials.gov. Open-label Multicenter Non-comparative Clinical Trial of Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of GNR-084 in Patients With Refractory or Relapse Acute Lymphoblastic B-cell Precursor Leukemia in Sequential Cohorts With Dose Escalation. Available at: www.clinicaltrials.gov (NCT04601584)."},{"key":"CIT0095","unstructured":"Clinicaltrials.gov. Phase \u2161 Clinical Trial of CNCT19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia. Available at: www.clinicaltrials.gov (NCT04684147)."},{"key":"CIT0096","unstructured":"Clinicaltrials.gov. A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies. Available at: www.clinicaltrials.gov (NCT04681105)."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/16078454.2022.2074704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T16:21:35Z","timestamp":1673022095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/16078454.2022.2074704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/16078454.2022.2074704"],"URL":"https:\/\/doi.org\/10.1080\/16078454.2022.2074704","relation":{},"ISSN":["1607-8454"],"issn-type":[{"value":"1607-8454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}